A Phase 1 interventional study of 9MW4113 injection and Dupilumab in Healthy Participants, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
It is a randomized, double-blinded, parallel, single-dose, Phase I comparative study to evaluate the pharmacokinetic, safety, and immunogenicity similarity between 9MW4113 and Dupixent® in healthy Chinese adult participants. A total of 208 healthy participants are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml 9MW4113 injection or Dupixent®.
Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
"9MW4113 injection; 300mg/2.0mL; subcutaneous injection. This group includes 104 patients."
Biological: 9MW4113 injection
"Dupixent®; 300mg/2.0mL; subcutaneous injection. This group includes 104 patients."
Biological: Dupilumab
"9MW4113 injection; 300mg/2.0mL; subcutaneous injection.
"Dupixent®; 300mg/2.0mL; subcutaneous injection.
Pharmacokinetics Endpoint
Maximum Concentration (Cmax)
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Area under the concentration-time curve time 0 to infinity (AUC0-∞)
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t)
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Time of maximum concentration (Tmax)
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Terminal elimination rate constant (λz)
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Terminal elimination half-life (t1/2z), t1/2z = ln2/λz
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Percentage of extrapolated area (AUC\_%Extrap), AUC\_%Extrap = \[(AUC0-∞-AUC0-t)/AUC0-∞\]×100%
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Apparent clearance (CL/F), CL/F=Dose/AUC0-∞
Time frame: 0-9weeks
Pharmacokinetics Endpoint
Apparent volume of distribution (Vd/F) , Vd/F = (CL/F)/λz
Time frame: 0-9weeks
Safety Assessments
adverse events, concomitant medications, concomitant non-drug therapies, injection site irritation assessment, laboratory tests (complete blood count, blood biochemistry test, urinalysis and coagulation function) clinical symptoms, vital signs , 12 lead ECGs, physical examination
Time frame: 0-9weeks
Incidence of anti-drug antibodies (ADA)
Time frame: 0-9weeks
Titer of anti-drug antibodies (ADA)
Time frame: 0-9weeks
Incidence of neutralizing antibodies (NAb)
Time frame: 0-9weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Jul 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mabwell (Shanghai) Bioscience Co., Ltd. →